Newsroom | 50864 results

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented final overall survival data from its pivotal Phase 3 ROSELLA trial of Lifyorli™ (relacorilant) combined with the chemotherapeutic agent nab-paclitaxel in patients with platinum-resis...

PORTO, Portugal--(BUSINESS WIRE)--Para acompañar el Día Mundial del Parkinson, Bial, una empresa biofarmacéutica orientada a la innovación y dedicada a neurociencias y enfermedades raras, lanza en el día de hoy “Diálogos con Parkinson”, una campaña educativa y de sensibilización de un año de duración diseñada para ayudar a una comunicación más clara entre personas que viven con Parkinson, sus cuidadores y profesionales de la salud. El comunicado en el idioma original es la versión oficial y aut...

PORTO, Portugal--(BUSINESS WIRE)--Anlässlich des Welt-Parkinson-Tages startet Bial, ein innovatives Biopharmaunternehmen mit Schwerpunkt auf Neurowissenschaften und seltenen Krankheiten, heute „Dialogues with Parkinson’s“ – eine einjährige Informations- und Sensibilisierungskampagne, um die Kommunikation zwischen Parkinson-Betroffenen, ihren Pflegepersonen und medizinischem Fachpersonal zu verbessern. Die in Zusammenarbeit mit Parkinson’s Europe ins Leben gerufene Initiative verbindet wissensch...

PORTO, Portogallo--(BUSINESS WIRE)--In occasione della Giornata Mondiale del Parkinson, Bial, azienda biofarmaceutica basata sull'innovazione e incentrata sulle neuroscienze e le malattie rare, oggi lancia “Dialogues with Parkinson’s”: una campagna di sensibilizzazione e informazione della durata di un anno, ideata per sostenere una più chiara comunicazione tra le persone affette dal morbo di Parkinson, i loro assistenti e i professionisti sanitari. Il testo originale del presente annuncio, red...

PORTO, Portugal--(BUSINESS WIRE)--À l’occasion de la Journée mondiale de la maladie de Parkinson, Bial, entreprise biopharmaceutique innovante spécialisée dans les neurosciences et les maladies rares, lance aujourd’hui « Dialogues avec la maladie de Parkinson », une campagne de sensibilisation et d’information d’une durée d'un an visant à améliorer la communication entre les personnes atteintes de la maladie de Parkinson, leurs aidants et les professionnels de santé. Développée en partenariat a...

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson showcases new clinical data for TECNIS PureSee IOL demonstrating excellent contrast sensitivity and extended range of vision...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced two-year median follow-up data from the Phase 2 RAMP 201 clinical trial that evaluated AVMAPKI® FAKZYNJA® combination therapy (avutometinib capsules; defactinib tablets) in patients with recurrent low-grade serous ovarian cancer (LGSOC) will be presented today during an oral plenary session at the Society o...

PORTO, Portugal--(BUSINESS WIRE)--To mark World Parkinson’s Day, Bial today launches “Dialogues with Parkinson’s”....

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced a poster presentation related to the company’s work on VE303, its defined bacterial consortium candidate for the prevention of recurrent Clostridioides difficile infection (CDI), and an oral presentation on VE707, its defined bacterial consortium candidate for the prevention of Gram-negative infections,...

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced its participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Ontario, Canada. TriSalus will showcase new clinical a...